The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
about
Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesionTherapeutic options for intrahepatic cholangiocarcinomaThe potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.Integrated mRNA and lncRNA expression profiling for exploring metastatic biomarkers of human intrahepatic cholangiocarcinoma.The emerging role of mast cells in liver disease.Current biologics for treatment of biliary tract cancers.Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness.Role of AP-2α and MAPK7 in the regulation of autocrine TGF-β/miR-200b signals to maintain epithelial-mesenchymal transition in cholangiocarcinoma.Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview.Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.New molecular and immunotherapeutic approaches in biliary cancer.Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.
P2860
Q33593231-B1FFB983-6720-40E4-9F18-F2F6CE02DCAAQ33621529-C9F910EB-04CE-43EB-B514-5EAD09BCC7F0Q33656860-CCF8145C-9E45-498B-85AC-E67B7A3EAE23Q37709171-8B2D070F-09E2-4773-ACC0-5E6EBCBAFB41Q37743528-2D7C910A-208C-448F-95E2-9FA815E90492Q39284642-D9E480DC-28B7-4B1F-922E-CE3E51441E4EQ39453572-7E111870-84EF-4F0E-9B1A-B993DF6A0F33Q39673531-226A96AF-6603-4935-A3F5-7E1DFF9431E0Q42371988-4D9EB72C-243E-46D0-8153-853EC14DBBF4Q45412331-051F42C3-E159-452F-BA92-0C8D5D489286Q47299042-C10BAD92-AD37-459F-94FF-C381A5966AC6Q47398665-D80A118B-610D-42A6-B03E-9A2657A7E01CQ47603972-F43E1303-4579-4996-B360-655B2D8D720BQ50127508-07D40575-8B95-492C-86D2-E05AB4E901A9Q54476966-1A6CE19B-061E-4BE7-BB63-D4C63BA5B961Q55260649-96705369-6E25-46C5-BA41-427ABD35F31F
P2860
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The landscape of targeted ther ...... nt status and emerging targets
@ast
The landscape of targeted ther ...... nt status and emerging targets
@en
The landscape of targeted ther ...... nt status and emerging targets
@nl
type
label
The landscape of targeted ther ...... nt status and emerging targets
@ast
The landscape of targeted ther ...... nt status and emerging targets
@en
The landscape of targeted ther ...... nt status and emerging targets
@nl
prefLabel
The landscape of targeted ther ...... nt status and emerging targets
@ast
The landscape of targeted ther ...... nt status and emerging targets
@en
The landscape of targeted ther ...... nt status and emerging targets
@nl
P2860
P921
P3181
P356
P1433
P1476
The landscape of targeted ther ...... nt status and emerging targets
@en
P2093
Andrew X Zhu
Dawn Q Chong
P2860
P3181
P356
10.18632/ONCOTARGET.8775
P407
P5008
P577
2016-04-18T00:00:00Z
2016-07-19T00:00:00Z